Coronavirus — I have Idiopathic Thrombocytopenic Purpura — Can I use Hydroxychloroquine? — Is there a risk?
To clearly understand the clinical aspects involved in Coronavirus This is an essential step for those seeking diagnostic certainty, lasting symptom relief, and prevention of complications. In the daily practice of Allergology and Clinical Immunology, questions related to... "Coronavirus — I have Idiopathic Thrombocytopenic Purpura — Can I use Hydroxychloroquine? — Is there a risk?" Allergy-free conditions are common among patients and their families. The goal of this page in the Brazil Allergy-Free Encyclopedia is to present a complete, accessible, and evidence-based medical analysis, detailing causes, immunological mechanisms, and safe practices.
✔ Medical content reviewed and validated by the founding clinical staff of the Brazil Without Allergies Project
Dr. Marcello Bossois (CRM-RJ 52.73214-1) · Dr. Patricia Schlinkert (CRM/RJ 5274541-3) — more than 30 years of history in Allergy and Immunology, with units in Rio de Janeiro, São Paulo and Paraná. Last reviewed: November 2026.
Patients with Idiopathic Thrombocytopenic Purpura (ITP) and Coronavirus Management
The concern of patients with hematological and autoimmune conditions, such as idiopathic thrombocytopenic purpura (ITP), regarding a possible coronavirus (Covid-19) infection is perfectly understandable. Questions about the use of specific medications, such as hydroxychloroquine—often mistakenly associated with anticoagulant properties—require extremely cautious, individualized medical analysis based on scientific rigor.
Hydroxychloroquine is a widely known drug that has been used for decades in various specialties, possessing a theoretical safety profile and well-established contraindications. However, the most relevant and concerning point in the context of Covid-19 lies not only in the medication itself, but also in the systemic inflammatory potential triggered by the virus, especially on the vascular endothelium.
The vascular endothelium—the inner layer lining blood vessels—can undergo severe inflammatory processes resulting from infection, which favors the formation of thrombi and increases the risk of thromboembolic complications. Since ITP already involves hematological and coagulation system particularities in the patient, viral infection adds a significant layer of complexity to the clinical picture.
One of the greatest challenges in the clinical management of Covid-19 is preventing the transition to the second phase of the disease, characterized by an exacerbated inflammatory response known as a cytokine storm. In this stage, there is a massive release of pro-inflammatory substances, such as interleukin-6 and tumor necrosis factor, in disharmony with anti-inflammatory cytokines. This imbalance increases the risk of thrombus formation and diffuse vascular damage.
Given such a complex scenario, therapeutic decision-making requires weighing the risks and benefits of each course of action, assessing the opportune moment to initiate more aggressive therapies that prevent progression to the more severe systemic phases of the disease. In patients with hematological comorbidities, rigorous monitoring and, often, early hospitalization under specialized medical supervision become fundamental strategies for comprehensive clinical support, allowing for the precise adjustment of therapeutic approaches and the preservation of physical integrity.
Explanatory note: This content is for educational and informational purposes only and should not, under any circumstances, replace consultation, diagnosis, and individualized medical evaluation with a qualified specialist.
Developments in Evidence-Based Medicine: Vaccine Immunology and Allergen-Specific Immunotherapy
In Evidence-Based Medicine (WHO, EAACI and ASBAI), two complementary strategies for modulating the immune system are distinguished: (1) the preventive anti-infectious immunizing vaccines, which stimulate humoral (neutralizing IgG/IgA antibodies) and cellular (memory T lymphocytes) adaptive immunity against viral and bacterial pathogens; and (2) a Allergen-specific immunotherapy (allergy vaccines), the only treatment that modifies the natural history of IgE-mediated allergic diseases. The controlled and progressive administration of standardized allergenic extracts promotes an immunological shift from the Th2 to the Th1 profile, inducing the expansion of regulatory T lymphocytes (CD4)+CD25+FOXP3+) producers of IL-10 and TGF-β and stimulates the synthesis of IgG4 subclass blocking antibodies, thus sustainably reducing clinical hyper-reactivity and the need for symptomatic drugs.
💎 Diamond Plan — Safe immunization, even for those with a history of allergies. Speak with an Allergy and Immunology specialist via teleconsultation, from anywhere in Brazil. Schedule a teleconsultation →
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Safe Immunization, Immune Response, and Protection of the Allergic Patient
Vaccine Mechanisms, Excipients, and Assessment of Immune Competence
Preventive immunization represents one of the greatest achievements of medicine in reducing hospitalizations and serious infectious complications, especially in patients with chronic respiratory diseases (such as asthma and COPD), heart disease, high blood pressure, and diabetes. Patients allergic to aeroallergens, foods, or common medications do not have a general contraindication to vaccines; allergological attention focuses on the specific evaluation of rare cases of previous anaphylaxis to isolated components of the formula (such as polyethylene glycol, polysorbate, or specific protein traces), situations that now have safe assisted application protocols.
Integration between Vaccination Schedule, Allergy Tests and Baseline Monitoring
Maintaining a controlled respiratory or immunological disease enhances the mucosal defense against seasonal viruses and enveloped bacteria. In case of doubt about the reaction history, the allergy test Specific information regarding excipients or associated allergens provides complete peace of mind before immunization, whereas continued use of the product is not recommended. allergy vaccine It preserves the immune system's balance throughout all seasons.
Th1/Th17 Inflammatory Axis, Environmental Triggers, and Epidermal Barrier
At the interface between Clinical Immunology, Dermatology, and Rheumatology, a systemic patient assessment allows for the early recognition of metabolic and joint comorbidities, as well as any coexisting hypersensitivities. Tests such as the Antinuclear Antibody (ANA) and inflammatory markers act as screening tools that only acquire real diagnostic significance when interpreted in light of a detailed physical examination of the skin, nails, scalp, and joints.
Immediate Reactions, Delayed Drug Reactions, and Risks of Self-Medication
Drug hypersensitivity reactions encompass distinct immunological and pharmacological mechanisms: from immediate reactions (up to one to six hours after dosing, manifested by urticaria, labial or palpebral angioedema, bronchospasm, and anaphylaxis, common with COX-1 inhibitor analgesics and beta-lactams) to delayed drug eruptions mediated by T cells, such as maculopapular rashes and DRESS syndrome — a systemic condition that arises weeks after the start of anticonvulsants, sulfones, or allopurinol, presenting with fever, lymphadenomegaly, eosinophilia, and the need for immediate discontinuation under hospital supervision.
Importance of Differential Diagnosis and Detailed Medical History
In the specialty of Allergy and Immunology, two patients with seemingly similar symptoms involving Coronavirus may present completely distinct pathophysiological mechanisms. For this reason, a thorough clinical history—investigating the chronology of crises, home and work environment, family history of atopy, use of concomitant medications, and dietary habits—serves as an indispensable compass for correctly interpreting laboratory tests (such as total and specific IgE levels) and functional tests. A single laboratory result can never replace in-person clinical judgment or specialized telemedicine, preventing misdiagnoses and unnecessary treatments.
Diamond Plan: Specialized Allergy Treatment Wherever You Are
Living hundreds of miles from an allergist or having to interrupt treatment because of the price of vaccines shouldn't be anyone's fate. With the Diamond PlanBrazil Without Allergies brings the same high standard of care from its clinics to your home, with telemedicine consultations and a more accessible path to immunotherapy. Safe immunization, even for those with a history of allergies.
Why do patients across Brazil choose the Diamond Plan?
- Teleconsultation with a specialist In Allergy and Immunology, without queues and without long commutes — ideal for those who live far from large cities.
- easy access to Immunotherapy (including allergy vaccines and immunostimulants) — indicated for the treatment of allergic rhinitis, asthma, bronchitis, atopic dermatitis, insect/mosquito bite allergy (prurigo strophulus), recurrent candidiasis, and for increasing immunity in selected patients — capable of modifying the natural course of allergic disease, always through consultation and individualized prescription.
- A more accessible route For those facing the high cost of allergy vaccines, this plan offers support for continuity of treatment.
- Continuous monitoring based on clinical evolution, with adjustments to treatment throughout the entire therapeutic cycle.
- National coverage, backed by a consolidated physical network and a founding clinical team with over three decades of experience.
More than 30 years caring for people with allergies.
Founded and run by Dr. Marcello Bossois (CRM-RJ 52.73214-1) and by Dr. Patrícia Schlinkert (CRM/RJ 5274541-3)The Brazil Without Allergies Project adds... more than 30 years of history and more than 450,000 free services, with physical presence at Rio de Janeiro, São Paulo and Paraná, one mobile clinic bus that brings testing and consultations to communities with limited access to specialized care and a platform of telemedicine which connects patients from all states to the same standard of care.
START TODAY
Your expert consultation is just a click away.
I want to join the Diamond Plan.Schedule a teleconsultation
Official telemedicine environment: brasilsemalergia.online
Do you prefer to be served in person?
Our clinical units They conduct consultations, allergy tests, and immunotherapy follow-up with doctors in person:
- Rio de Janeiro: Realengo (West Zone), North Zone, Duke of Caxias, Xerém, New Iguaçu, Itaguaí, Niterói, Iguaba Grande and Saint Peter of the Village (Lakes Region).
- São Paulo: Campo Limpo (South Zone).
- Paraná: Curitiba.
Schedule your in-person appointment. Or check the mobile bus schedule through the customer service center on WhatsApp. (21) 99954-5632.
The indication for immunotherapy, and for any treatment, depends on an individual medical evaluation. This content is for informational purposes only and does not replace consultation with a specialist.
Note: Subject to prior medical evaluation (in person or via telemetry/telemedicine). Immunotherapy uses allergen-specific vaccines, which requires a prescription from the attending physician and must be administered under direct medical supervision.
Conclusion and Summary of Guidelines
In summary, the appropriate approach to Coronavirus This requires a clear understanding of the immunological mechanisms involved, precise etiological diagnosis, and individualized medical follow-up. Avoid self-medication and investigate the root cause of symptoms—relying on specialized resources and reliable guidance such as... rhinitis treatment When clinically relevant, it is the safest way to manage crises, prevent complications, and ensure sustainable quality of life.
Scientific references and authoritative sources
The guidelines on this page follow the guidelines and literature of leading international Allergy and Immunology institutions. For further information:




